Enhanced snoMEN Vectors Facilitate Institution of GFP-HIF-1α Protein Substitute Human Cell Traces.
The snoMEN (snoRNA Modulator of gene ExpressioN) vector expertise was developed from a human field C/D snoRNA, HBII-180C, which accommodates an inside sequence that may be manipulated to make it complementary to RNA targets, permitting knock-down of focused genes. Right here we’ve got screened further human nucleolar snoRNAs and assessed their software for gene particular knock-downs to enhance the effectivity of snoMEN vectors.
We establish and characterise a brand new snoMEN vector, termed 47snoMEN, that’s derived from field C/D snoRNA U47, demonstrating its use for knock-down of each endogenous mobile proteins and G/YFP-fusion proteins.
Utilizing multiplex 47snoMEM vectors that co-express a number of 47snoMEN in a single transcript, every of which may goal totally different websites in the identical mRNA, we doc >3-fold improve in knock-down effectivity when put next with the unique HBII-180C primarily based snoMEN.
The multiplex 47snoMEM vector allowed the development of human protein alternative cell traces with improved effectivity, together with the institution of novel GFP-HIF-1α alternative cells.
Quantitative mass spectrometry evaluation confirmed the improved effectivity and specificity of protein alternative utilizing the 47snoMEN-PR vectors. The 47snoMEN vectors develop the potential purposes for snoMEN expertise in gene expression research, goal validation and gene remedy
gfpvector
Nacc1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL503738 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
NACC2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL306355 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
NACC2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV697081 | ABM | 1.0 ug DNA | EUR 818.4 |
NACC2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV697085 | ABM | 1.0 ug DNA | EUR 818.4 |
NACC2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV697086 | ABM | 1.0 ug DNA | EUR 818.4 |
NACC1 ORF Vector (Human) (pORF) |
|||
| ORF025872 | ABM | 1.0 ug DNA | EUR 486 |
NACC2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV697082 | ABM | 1.0 ug DNA | EUR 818.4 |
NACC2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV697083 | ABM | 1.0 ug DNA | EUR 888 |
NACC2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV697084 | ABM | 1.0 ug DNA | EUR 888 |
Nacc2 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL704108 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
NACC1 Protein Vector (Human) (pPM-C-HA) |
|||
| PV103488 | ABM | 500 ng | EUR 662.4 |
Nacc2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL509815 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
NACC1 Protein Vector (Human) (pPB-C-His) |
|||
| PV103486 | ABM | 500 ng | EUR 662.4 |
NACC1 Protein Vector (Human) (pPB-N-His) |
|||
| PV103487 | ABM | 500 ng | EUR 662.4 |
NACC1 Protein Vector (Human) (pPM-C-His) |
|||
| PV103489 | ABM | 500 ng | EUR 662.4 |
NACC1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL306354V | Origene Technologies GmbH | 500 ul each | Ask for price |
Nacc1 ORF Vector (Rat) (pORF) |
|||
| ORF071065 | ABM | 1.0 ug DNA | EUR 607.2 |
Nacc1 ORF Vector (Mouse) (pORF) |
|||
| ORF050990 | ABM | 1.0 ug DNA | EUR 607.2 |
NACC1 sgRNA CRISPR Lentivector set (Human) |
|||
| K1386401 | ABM | 3 x 1.0 ug | EUR 406.8 |
NACA3P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV771605 | ABM | 1.0 ug DNA | EUR 1173.6 |
NACA3P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV771609 | ABM | 1.0 ug DNA | EUR 1173.6 |
NACA3P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV771610 | ABM | 1.0 ug DNA | EUR 1173.6 |
NACC1 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV284260 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Rat) (pPB-C-His) |
|||
| PV284258 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Rat) (pPB-N-His) |
|||
| PV284259 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Rat) (pPM-C-His) |
|||
| PV284261 | ABM | 500 ng | EUR 723.6 |
NACC1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1386402 | ABM | 1.0 ug DNA | EUR 184.8 |
NACC1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1386403 | ABM | 1.0 ug DNA | EUR 184.8 |
NACC1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1386404 | ABM | 1.0 ug DNA | EUR 184.8 |
NACC1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV203960 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV203958 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV203959 | ABM | 500 ng | EUR 723.6 |
NACC1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV203961 | ABM | 500 ng | EUR 723.6 |
NACC1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR306354 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | EUR 379.2 |
Nacc1 - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL712823V | Origene Technologies GmbH | 500 ul each | Ask for price |
Human NACC1 siRNA |
|||
| 20-abx903454 | Abbexa |
|
|
NACC1 siRNA (Human) |
|||
| MBS8214139-15nmol | MyBiosource | 15nmol | EUR 405 |
NACC1 siRNA (Human) |
|||
| MBS8214139-30nmol | MyBiosource | 30nmol | EUR 565 |
NACC1 siRNA (Human) |
|||
| MBS8214139-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
NACA3P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV771606 | ABM | 1.0 ug DNA | EUR 1173.6 |
NACA3P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV771607 | ABM | 1.0 ug DNA | EUR 1243.2 |
NACA3P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV771608 | ABM | 1.0 ug DNA | EUR 1243.2 |
HP Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV703719 | ABM | 1.0 ug DNA | EUR 540 |
HP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703723 | ABM | 1.0 ug DNA | EUR 540 |
C5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV704421 | ABM | 1.0 ug DNA | EUR 540 |
C5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV704425 | ABM | 1.0 ug DNA | EUR 540 |
CS Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV709011 | ABM | 1.0 ug DNA | EUR 379.2 |
CS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV709015 | ABM | 1.0 ug DNA | EUR 379.2 |
MS Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV734267 | ABM | 1.0 ug DNA | Ask for price |
MS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV734271 | ABM | 1.0 ug DNA | Ask for price |
NA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV735845 | ABM | 1.0 ug DNA | Ask for price |
NA Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV735849 | ABM | 1.0 ug DNA | Ask for price |
NM Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV736283 | ABM | 1.0 ug DNA | Ask for price |
NM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV736287 | ABM | 1.0 ug DNA | Ask for price |
XM Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV756071 | ABM | 1.0 ug DNA | Ask for price |
XM Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756075 | ABM | 1.0 ug DNA | Ask for price |
XS Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV756089 | ABM | 1.0 ug DNA | Ask for price |
XS Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV756093 | ABM | 1.0 ug DNA | Ask for price |
IV Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV730175 | ABM | 1.0 ug DNA | Ask for price |
IV Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV730179 | ABM | 1.0 ug DNA | Ask for price |
S7 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV747677 | ABM | 1.0 ug DNA | Ask for price |
S7 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV747681 | ABM | 1.0 ug DNA | Ask for price |
P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV739457 | ABM | 1.0 ug DNA | Ask for price |
P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV739461 | ABM | 1.0 ug DNA | Ask for price |
NP Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV814299 | ABM | 1.0 ug DNA | EUR 540 |
NP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV814303 | ABM | 1.0 ug DNA | EUR 540 |
HGF Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV701979 | ABM | 1.0 ug DNA | EUR 540 |
HGF Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV701983 | ABM | 1.0 ug DNA | EUR 540 |
C8A Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV702501 | ABM | 1.0 ug DNA | EUR 540 |
C8A Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702505 | ABM | 1.0 ug DNA | EUR 540 |
SLN Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV702969 | ABM | 1.0 ug DNA | EUR 540 |
SLN Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV702973 | ABM | 1.0 ug DNA | EUR 540 |
CRP Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV703479 | ABM | 1.0 ug DNA | EUR 540 |
CRP Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703483 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV703695 | ABM | 1.0 ug DNA | EUR 540 |
NPL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703699 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV703815 | ABM | 1.0 ug DNA | EUR 540 |
LY9 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV703819 | ABM | 1.0 ug DNA | EUR 540 |
FGA Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV704103 | ABM | 1.0 ug DNA | EUR 540 |
A replicating plasmid-based vector for GFP expression in Mycoplasma hyopneumoniae.
Mycoplasma hyopneumoniae (M. hyopneumoniae) causes porcine enzootic pneumonia (PEP) that considerably impacts the pig trade worldwide. Regardless of the provision of the entire genome sequence, research on the pathogenesis of this organism have been restricted as a result of lack of a genetic manipulation system.
Subsequently, the intention of the present examine was to generate a common GFP reporter vector primarily based on a replicating plasmid. Right here, we describe the feasibility of GFP reporter expression in M. hyopneumoniae (pressure 168L) managed by the p97 gene promoter of this mycoplasma. An expression plasmid (pMD18-TOgfp) containing the p97 gene promoter, and origin of replication (oriC) of M. hyopneumoniae, tetracycline resistant marker (tetM), and GFP was constructed and used to rework competent M. hyopneumoniae cells.
We noticed inexperienced fluorescence in M. hyopneumoniae transformants beneath fluorescence microscopy, which signifies that there was expression of the GFP reporter that was pushed by the p97 gene promoter.
Moreover, an electroporation methodology for M. hyopneumoniae with an effectivity of roughly 1 x 10(-6) transformants/μg plasmid DNA was optimized and is described herein. In conclusion, our information display the susceptibility of M. hyopneumoniae to genetic manipulation whereby overseas genes are expressed. This work might encourage the event of genetic instruments to govern the genome of M. hyopneumoniae for practical genomic analyses.
Human adipose derived mesenchymal stromal cells transduced with GFP lentiviral vectors: evaluation of immunophenotype and differentiation capability in vitro.
Adipose derived mesenchymal stromal/stem cells (ASCs) are a heterogeneous inhabitants characterised by (a) their potential to stick to plastic; (b) immunophenotypic expression of sure cell floor markers, whereas missing others; and (c) the capability to distinguish into lineages of mesodermal origin together with osteocytes, chondrocytes and adipocytes. The long-term objective is to make the most of these cells for medical translation into cell-based therapies. Nonetheless, preclinical security and efficacy have to be demonstrated in animal fashions.
ASCs will also be utilized as organic autos for vector-based gene supply techniques, since they’re believed to dwelling to websites of irritation and an infection in vivo. These elements motivated the event of a labelling system for ASCs utilizing lentiviral vector-based inexperienced fluorescent protein (GFP) transduction. Human ASCs had been transduced with GFP-expressing lentiviral vectors. A titration examine decided the viral titer required to transduce the utmost variety of ASCs.
The impact of the transduced GFP lentiviral vector on ASC immunophenotypic expression of floor markers in addition to their potential to distinguish into osteocytes and adipocytes had been assessed in vitro.
Transduction effectivity in ASC cultures of roughly 80 % was noticed with an MOI of ~118. No important immunophenotypic variations had been noticed between transduced and non-transduced cells and each cell sorts efficiently differentiated into adipocytes and osteocytes in vitro. We obtained >80 % transduction of ASCs utilizing GFP lentiviral vectors.
Transduced ASCs maintained plastic adherence, demonstrated ASC immunophenotype and the flexibility to distinguish into cells of the mesodermal lineage. This GFP-ASC transduction approach provides a possible monitoring system for future pre-clinical research.
Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip |
|||
| 0-120-0018 | Biologics | 25 mm | EUR 100 |
|
Description: use with corresponding Tapped Tips and Tapped Extender Tips |
|||
Titanium Cup Tip, 250 ml |
|||
| 0-120-0019 | Biologics | 250 ml | EUR 1377 |
|
Description: includes Interface Washers |
|||
Microtube Tray, 8 Position (for 250 ml Cup Tip) |
|||
| 0-120-0021 | Biologics | each | EUR 113 |
|
Description: includes Interface Washers |
|||
Continuous Flow Chamber |
|||
| 0-120-0026 | Biologics | each | EUR 774 |
|
Description: includes Interface Washers |
|||
Interface Washers 1.5” Diameter, 5/Pkg |
|||
| 0-120-003 | Biologics | 1.5'' Diameter | EUR 31 |
13 mm Diameter Solid Titanium Extender Tip |
|||
| 0-120-0032 | Biologics | 13 mm | EUR 301 |
13 mm Diameter Tapped Titanium Extender Tip |
|||
| 0-120-0033 | Biologics | 13 mm | EUR 362 |
19 mm Diameter Solid Titanium Extender Tip |
|||
| 0-120-0034 | Biologics | 19 mm | EUR 315 |
19 mm Diameter Tapped Titanium Extender Tip |
|||
| 0-120-0035 | Biologics | 19 mm | EUR 375 |
25 mm Diameter Solid Titanium Extender Tip |
|||
| 0-120-0036 | Biologics | 25 mm | EUR 328 |
25 mm Diameter Tapped Titanium Extender Tip |
|||
| 0-120-0037 | Biologics | 25 mm | EUR 389 |
KoldPod, 1.5ml Micro Tube |
|||
| 0-120-0038 | Biologics | 1.5 ml | EUR 152 |
|
Description: Thermo conductive tube pods |
|||
KoldPod, 15ml Conical Tube |
|||
| 0-120-0039 | Biologics | 15 ml | EUR 275 |
|
Description: Thermo conductive tube pods |
|||
KoldPod, 50ml Conical Tube |
|||
| 0-120-0040 | Biologics | 50 ml | EUR 290 |
|
Description: Thermo conductive tube pods |
|||
Model 150 V/T Ultrasonic Homogenizer |
|||
| 0-121-0002 | Biologics | 210-240V/50-60Hz | EUR 2920 |
|
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing. |
|||
Model 300 V/T Ultrasonic Homogenizer |
|||
| 0-122-0002 | Biologics | 210-240V/50-60Hz | EUR 3520 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample. |
|||
SONABOZ Sound Abating Chamber |
|||
| 0-125-0001 | Biologics | each | EUR 1020 |
|
Description: Reduces cavitational sound emitted during processing. |
|||
Model 3000 Ultrasonic Homogenizer |
|||
| 0-127-0002 | Biologics | 210-240V/50-60Hz | EUR 4120 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample. |
|||
Model 3000MP Ultrasonic Homogenizer |
|||
| 0-128-0002 | Biologics | 210-240V/50-60Hz | EUR 4720 |
|
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing. |
|||
OMNICON® Zone Reader, 210-240V/50-60Hz |
|||
| 0-131-0002 | Biologics | 210-240V/50-60Hz | EUR 35200 |
|
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media. |
|||
OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz |
|||
| 0-134-0002 | Biologics | 210-240V/50-60Hz | EUR 32200 |
|
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample. |
|||
Peni Cylinder Dispenser with Manual Hopper |
|||
| 0-144-0002 | Biologics | each | EUR 5406 |
|
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish. |
|||
Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz |
|||
| 0-144-0003 | Biologics | 100-240V/50-60Hz | EUR 6254 |
|
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection. |
|||
Stainless Steel Peni Cylinder with Flat Face |
|||
| 0-144-0005 | Biologics | 6mm I.D. x 8mm O.D. x 10mm Long | EUR 399 |
|
Description: sold in packages of 100 pieces |
|||
Stainless Steel Peni Cylinder with Chamfered Face |
|||
| 0-144-0006 | Biologics | 6mm I.D. x 8mm O.D. x 10mm Long | EUR 412 |
|
Description: sold in packages of 100 pieces |
|||
Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA) |
|||
| 000-CUS | Alpha Diagnostics | Custom | EUR 602 |
Alpha-Bungarotoxin, CF®405S, 500 ug |
|||
| 00002 | Biotium | 1UG | EUR 527 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-bungarotoxin, CF405s |
|||
| 00002 | Cusabio | 500uG | EUR 594 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF®405S, 500 ug |
|||
| 00002-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®405S 100ug |
|||
| 00002-100ug | Biotium | 100uG | EUR 132 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®680R, 500 ug |
|||
| 9-00003 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®680R, 500 ug |
|||
| 00003-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®680R 100ug |
|||
| 9-00003 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®640R, 500 ug |
|||
| 9-00004 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®640R, 500 ug |
|||
| 00004-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®640R 100ug |
|||
| 9-00004 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®488A, 500 ug |
|||
| 9-00005 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®488A, 500 ug |
|||
| 00005-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin CF®488A 100ug |
|||
| 9-00005 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®568, 500 ug |
|||
| 9-00006 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®568, 500 ug |
|||
| 00006-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®568 100ug |
|||
| 9-00006 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®594, 500 ug |
|||
| 9-00007 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®594, 500 ug |
|||
| 00007-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin CF®594 100ug |
|||
| 9-00007 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®633, 500 ug |
|||
| 9-00009 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®633, 500 ug |
|||
| 00009-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®633 100ug |
|||
| 9-00009 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
SARS-CoV-2 Indicator Cell Line for RNA Replication - GFP Reporter only |
|||
| 0001-PP-001 | IBT Bioservices | 1 cell line (can order x amount) | EUR 12000 |
|
Description: SARS-CoV-2 GFP reporter cell line using HEK293T (ACE2/TMPRSS2) cells |
|||
Alpha-Bungarotoxin, 1 mg |
|||
| 00010-1 | Biotium | 1MG | EUR 193 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, 1 mg |
|||
| 00010-1-1 | Biotium | EA | EUR 193 |
Fluorescein-Alpha-Bungarotoxin, 500 ug |
|||
| 00011 | Biotium | 500uG | EUR 376 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Fluorescein-Alpha-Bungarotoxin, 500 ug |
|||
| 00011-1 | Biotium | EA | EUR 376 |
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
|||
| 00012 | Biotium | 500uG | EUR 394 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug |
|||
| 00012-1 | Biotium | EA | EUR 394 |
Fluorescein-alpha-bungarotoxin, 10x50ug |
|||
| 00013 | Biotium | 10ST | EUR 436 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Fluorescein-alpha-bungarotoxin, 10x50ug |
|||
| 00013-1 | Biotium | EA | EUR 436 |
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
|||
| 00014 | Biotium | 10ST | EUR 494 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug |
|||
| 00014-1 | Biotium | EA | EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
|||
| 00015 | Biotium | 500uG | EUR 494 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug |
|||
| 00015-1 | Biotium | EA | EUR 494 |
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
|||
| 00016 | Biotium | 10ST | EUR 560 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug |
|||
| 00016-1 | Biotium | EA | EUR 560 |
Biotin-XX-A-Bungarotoxin, 500 ug |
|||
| 00017 | Biotium | 500uG | EUR 455 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Biotin-XX-A-Bungarotoxin, 500 ug |
|||
| 00017-1 | Biotium | EA | EUR 455 |
Alpha-Bungarotoxin, CF®555, 500 ug |
|||
| 9-00018 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®555, 500 ug |
|||
| 00018-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®555 100ug |
|||
| 9-00018 | Biotium |
|
|
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Acrylamide, Chemzymes Ultra Pure® |
|||
| 00019-100 | Polysciences Europe GmbH | 100g | EUR 101.52 |
|
Description: 79-06-1 |
|||
Acrylamide, Chemzymes Ultra Pure® |
|||
| 00019-500 | Polysciences Europe GmbH | 500g | EUR 270 |
|
Description: 79-06-1 |
|||
Biotin-cAMP, 1 mg |
|||
| 00020 | Biotium | 1MG | EUR 298 |
|
Description: N/A |
|||
Biotin-cAMP, 1 mg |
|||
| 00020-1 | Biotium | 20ST | EUR 298 |
|
Description: N/A |
|||
Biotin-cAMP, 50 ug |
|||
| 00020-1-1 | Biotium | EA | EUR 414 |
Biotin-cGMP, 1 mg |
|||
| 00021 | Biotium | 1MG | EUR 331 |
|
Description: N/A |
|||
Biotin-cGMP, 1 mg |
|||
| 00021-1 | Biotium | 20ST | EUR 331 |
|
Description: N/A |
|||
Biotin-cGMP, 20x50 ug |
|||
| 00021-1-1 | Biotium | EA | EUR 447 |
Cyanine 644-cAMP, 1 mg |
|||
| 00022 | Biotium | 1MG | EUR 496 |
|
Description: N/A |
|||
Cyanine 644-cAMP, 1 mg |
|||
| 00022-1 | Biotium | 20ST | EUR 496 |
|
Description: N/A |
|||
Cyanine 644-cAMP, 20x50 ug |
|||
| 00022-1-1 | Biotium | EA | EUR 647 |
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
|||
| 00023 | Biotium | 1MG | EUR 285 |
|
Description: N/A |
|||
Fluorescein Methotrexate, Triammonium Salt, 1 mg |
|||
| 00023-1 | Biotium | EA | EUR 285 |
Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 100 |
|
Description: N/A |
|||
Staurosporine |
|||
| 00025-1 | Biotium | EA | EUR 100 |
Alpha-Bungarotoxin, CF®543, 500 ug |
|||
| 00026 | Biotium | 500uG | EUR 527 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||
Alpha-Bungarotoxin, CF®543, 500 ug |
|||
| 00026-1 | Biotium | EA | EUR 527 |
Alpha-Bungarotoxin, CF®543, 100 ug |
|||
| 00026-100ug | Biotium | 1UG | EUR 132 |
|
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus) |
|||